Financing & funding
Cost of syringes: UNICEF procurement US$ 0.028 to US$ 0.065 depending on supplier and product / PAHO RF procurement US$ 0.028 to US$ 0.048 depending on supplier and product. Go to footnote 1, Go to footnote 2, Go to footnote 3
Cost of safety boxes: UNICEF procurement, a box of 25 safety boxes (each with a 5-liter capacity) is about US$ 20.26, resulting in approximately US$ 0.81 per safety box. Each 5-liter safety box can hold around 100 syringes, leading to a disposal cost of approximately US$ 0.008 per syringe. Go to footnote 3, Go to footnote 4
As of June 2026, the UNICEF price per dose for 2026 for countries accessing Gavi prices, ranges between US$ 2.00 for PCV10, 5 doses presentation (Serum Institute of India) and US$ 3.30 for PCV13 single dose presentation (Pfizer). Prices are expected to change in 2027 starting from US$ 1.55 for PCV10, 5 doses presentation (Serum Institute of India). For Middle Income Countries (MICs), UNICEF prices per dose for 2026 range between US$ 4.00 and US$ 18.05 depending on country income level, supplier, valency and presentation. Prices for humanitarian use and countries in fragile states range between US$ 2.00 and US$ 7.00 depending on country, supplier, valency and presentation. Go to footnote 5
UNICEF prices are subject to change. Access to the most up to date price can be found at the following link: Pneumococcal Conjugate Vaccine (PCV) price data | UNICEF Supply Division(1) Users are encouraged to confirm those prices by contacting UNICEF Supply Division.
As per the 2025 PAHO price list, the price per dose for the Revolving Fund for Access to Vaccines ranges between US$ 2.00-2.90 for PCV10, US$ 13.50 for PCV13, and US$ 20.00 for PCV20. Go to footnote 6
As per the April 2026 US CDC pricelist, the cost per dose of pediatric PCV vaccine in the United States ranges between US$184.18 and US$200.13. Go to footnote 7
As per the 2024 WHO/UNICEF Joint Reporting Form reported data, the price per dose for self-procuring MICs is on average US$ 19.20 (range US$ 3.03-59.32 depending on country income level, supplier and valency). Go to footnote 8
Cost of delivery (health facility based): ranges between US$ 0.06 and US$ 3.96 per dose. Go to footnote 9, Go to footnote 10, Go to footnote 11, Go to footnote 12, Go to footnote 13, Go to footnote 14
The cost–effectiveness of PCV use depends on many factors, including the burden of disease, vaccine effectiveness, indirect effects, vaccination coverage, vaccine price, delivery costs and schedule. Go to footnote 15, Go to footnote 16 An analysis of data from 22 studies in low- and middle-income countries showed that vaccination with PCV10-GSK and PCV13-PFZ using a 3p+0 or 2p+1 schedule is cost-effective from the perspectives of both the healthcare system and society. Go to footnote 16 The cost-effectiveness according to product choice will depend on country characteristics, including local serotype distribution and coverage rates achieved with different schedules. Go to footnote 15, Go to footnote 16, Go to footnote 17, Go to footnote 18
Gavi supports PCV introduction since 2009 with use of Pneumococcal Advance Market Commitment up to 2020. Contracts with manufacturers continue through 2029. Gavi provides support for routine introduction and catch-up introduction funding PCVs and injection supplies and vaccine introduction grants. Go to footnote 19
- Go back to footnote reference 1
UNICEF (2025). Auto-disable (AD) syringe price data. UNICEF Supply Division. Updated January 2025. Available at: https://www.unicef.org/supply/documents/auto-disable-ad-syringe-price-data (accessed 5 August 2025)
- Go back to footnote reference 2
Pan American Health Organization (PAHO) (2024). Revolving Fund syringe prices 2024. PAHO/WHO Revolving Fund for Access to Vaccines. Last update April 2024. Available at: https://www.paho.org/en/documents/revolving-fund-syringe-prices-2024 (accessed 5 August 2025)
- Go back to footnote reference 3aGo back to footnote reference 3b
UNICEF (2025). Syringe and safety box bundles price data. UNICEF Supply Division. Updated early 2025. Available at: https://www.unicef.org/supply/documents/syringe-and-safety-box-bundles-price-data (accessed 5 August 2025)
- Go back to footnote reference 4
Safety box price data. UNICEF Supply Division. Updated January 2025. Available at: https://www.unicef.org/supply/documents/safety-boxes-price-data (accessed 5 August 2025)
- Go back to footnote reference 5
UNICEF (2026). Pneumococcal conjugate vaccine (PCV) price data. United Nations Children’s Fund. Available at: https://www.unicef.org/supply/documents/pneumococcal-conjugate-vaccine-pcv-price-data (accessed 16 June 2026).
- Go back to footnote reference 6
Pan American Health Organization (PAHO) (2025). Vaccine prices 2025. Pan American Health Organization. Available at: https://www.paho.org/sites/default/files/2025-07/prices-vac-2025-eng-2-july-2025-v3.pdf (accessed 16 June 2026).
- Go back to footnote reference 7
Centers for Disease Control and Prevention (CDC) (2026). Current CDC vaccine price list. U.S. Department of Health and Human Services. Available at: https://www.cdc.gov/vaccines-for-children/media/pdfs/2026/03/Pediatric-VFC-Vaccine-Price-List-04-01-26-508.pdf (accessed 16 June 2026).
- Go back to footnote reference 8
World Health Organization (2025). 2025 MI4A public vaccine purchase dataset. World Health Organization. Available at: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data (accessed 16 June 2026).
- Go back to footnote reference 9
AMP (2014). Costing and financing analyses of routine immunization and new vaccine introduction in Benin: Final report. Agence de Médecine Préventive. Acailable at https://immunizationeconomics.org/wp-content/uploads/2024/01/FINALREPORT_BENIN.pdf (accessed 5 Aug 2025)
- Go back to footnote reference 10
Guthrie T, Zikusooka C, Kwesiga B, Abewe C, Lagony S et al. (2014). Costing and financing analyses of routine immunization in Uganda. Health Economics and HIV and AIDS Research Division (HEARD), University of KwaZulu-Natal.
- Go back to footnote reference 11
Bem J and Stewart E (2015). Vaccine costing analysis: Preliminary results. Presentation at the Pharmaceutical Fund and Supply Agency, Addis Ababa, Ethiopia, September 2015.
- Go back to footnote reference 12
Ngabo F, Levin A, Wang SA, Gatera M, Rugambwa C et al. (2015). A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. Vaccine, 33(51), pp.7357–7363. https://doi.org/10.1016/j.vaccine.2015.10.022
- Go back to footnote reference 13
Dorji K, Phuntsho S, Pempa, Kumluang S, Khuntha S et al. (2018). Towards the introduction of pneumococcal conjugate vaccines in Bhutan: a cost-utility analysis to determine the optimal policy option. Vaccine, 36(13), pp.1757–1765. https://doi.org/10.1016/j.vaccine.2018.02.048
- Go back to footnote reference 14
ThinkWell (2024). Immunization delivery cost catalogue (IDCC). Available at: https://immunizationeconomics.org/recent-activity/2024/6/11/immunization-delivery-cost-catalogue/ (accessed 5 August 2025).
- Go back to footnote reference 15aGo back to footnote reference 15b
Chaiyakunapruk N, Somkrua R, Hutubessy R, Henao AM, Hombach J, Melegaro A et al. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Med. 2011;9:53. doi: 10.1186/1741-7015-9-53.
- Go back to footnote reference 16aGo back to footnote reference 16bGo back to footnote reference 16c
Saokaew S, Rayanakorn A, Wu DB, Chaiyakunapruk N. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. Pharmacoeconomics. 2016;34:1211-25. doi: 10.1007/s40273-016-0439-3.
- Go back to footnote reference 17
Krishnamoorthy Y, Eliyas SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. Vaccine. 2019;37:623-30. doi: 10.1016/j.vaccine.2018.12.004.
- Go back to footnote reference 18
Dilokthornsakul P, Kengkla K, Saokaew S, Permsuwan U, Techasaensiri C, Chotpitayasunondh T et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 2019;37:4551-60. doi: 10.1016/j.vaccine.2019.06.015.
- Go back to footnote reference 19
Gavi, the Vaccine Alliance (2022). Vaccine Funding Guidelines. Gavi, the Vaccine Alliance. Available at: https://www.gavi.org/sites/default/files/document/2022/Vaccine_FundingGuidelines_0.pdf (accessed 5 August 2025.
